In:
Cancer, Wiley, Vol. 119, No. 18 ( 2013-09), p. 3334-3342
Abstract:
The PIAF (cisplatin/interferon α‐2b/doxorubicin/5‐fluorouracil) regimen can be tolerable and achieve high response rate in patients with hepatocellular carcinoma who do not have hepatitis or cirrhosis. With modification of the treatment protocol, the PIAF regimen achieved a high rate of conversion to curative surgery (33%) and prolonged survival (median of 21.3 months) in patients with initially unresectable tumor.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v119.18
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink